# A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

> **NCT04502446** · PHASE1 · TERMINATED · sponsor: **CRISPR Therapeutics AG** · enrollment: 49 (actual)

## Conditions studied

- T Cell Lymphoma

## Interventions

- **BIOLOGICAL:** CTX130

## Key facts

- **NCT ID:** NCT04502446
- **Lead sponsor:** CRISPR Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-31
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Patients to be followed up in the CRSP-ONC-LTF study
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04502446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04502446, "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04502446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*